ME02102B - Novi polimorf - Google Patents

Novi polimorf

Info

Publication number
ME02102B
ME02102B MEP-2015-56A MEP5615A ME02102B ME 02102 B ME02102 B ME 02102B ME P5615 A MEP5615 A ME P5615A ME 02102 B ME02102 B ME 02102B
Authority
ME
Montenegro
Prior art keywords
new polymorph
polymorph
new
Prior art date
Application number
MEP-2015-56A
Other languages
English (en)
Inventor
Björn Erik Johanson
Johan Henrik Kjellström
Thomas Vilhelmsen
Original Assignee
Vantia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vantia Ltd filed Critical Vantia Ltd
Publication of ME02102B publication Critical patent/ME02102B/me

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
MEP-2015-56A 2010-04-01 2011-03-31 Novi polimorf ME02102B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1005623.2A GB201005623D0 (en) 2010-04-01 2010-04-01 New polymorph
US34704810P 2010-05-21 2010-05-21
PCT/GB2011/000500 WO2011121308A1 (en) 2010-04-01 2011-03-31 New polymorph
EP11714079.8A EP2552910B1 (en) 2010-04-01 2011-03-31 New polymorph

Publications (1)

Publication Number Publication Date
ME02102B true ME02102B (me) 2015-10-20

Family

ID=42228830

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2015-56A ME02102B (me) 2010-04-01 2011-03-31 Novi polimorf

Country Status (20)

Country Link
US (1) US9079881B2 (me)
EP (1) EP2552910B1 (me)
JP (1) JP5802737B2 (me)
KR (1) KR101792621B1 (me)
CN (1) CN102918038B (me)
CA (1) CA2795109C (me)
DK (1) DK2552910T3 (me)
ES (1) ES2538085T3 (me)
GB (1) GB201005623D0 (me)
HR (1) HRP20150513T1 (me)
HU (1) HUE026442T2 (me)
ME (1) ME02102B (me)
MX (1) MX2012011382A (me)
PL (1) PL2552910T3 (me)
PT (1) PT2552910E (me)
RS (1) RS53956B1 (me)
RU (1) RU2559633C2 (me)
SI (1) SI2552910T1 (me)
SM (1) SMT201500107B (me)
WO (1) WO2011121308A1 (me)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201105537D0 (en) * 2011-03-31 2011-05-18 Vantia Ltd New process
CN104059070B (zh) * 2013-09-17 2016-02-10 天津药物研究院有限公司 利希普坦晶型ⅰ及其制备方法和用途
CN103755707B (zh) * 2013-09-17 2015-11-18 天津药物研究院 利希普坦晶型ⅱ及其制备方法和用途
CN103694240B (zh) * 2013-09-18 2015-11-18 天津药物研究院 利希普坦的溶剂合物及其制备方法和用途
CN104140429B (zh) * 2014-07-25 2015-11-18 天津药物研究院 利希普坦晶型ⅴ及其制备方法和用途
EP3325456A4 (en) 2015-07-22 2019-01-23 Anavex Life Sciences Corp. CRYSTAL FORMS OF TETRA-HYDRO-N, N-DIMETHYL-2,2-DIPHENYL-3-FURANOMETHANAMINE HYDROCHLORIDE, METHOD FOR THE PREPARATION OF SUCH FORMS, AND THEIR PHARMACEUTICAL COMPOSITIONS
WO2020154581A1 (en) 2019-01-24 2020-07-30 Assia Chemical Industries Ltd Solid state forms of fedovapagon-salicyclic acid co-crystal

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW359669B (en) 1995-12-15 1999-06-01 Otsuka Pharma Co Ltd Benzazepine derivatives
NZ502448A (en) 1997-07-30 2002-12-20 Wyeth Corp Tricyclic vasopressin agonists and medicaments containing these compounds
DK1000062T3 (da) 1997-07-30 2004-11-22 Wyeth Corp Tricykliske vasopressinagonister
DE60000969D1 (de) 1999-02-04 2003-01-23 Wyeth Corp Pyrrolobenzodiazepine carboxamide vasopressin agonisten
JP2002536377A (ja) 1999-02-04 2002-10-29 ワイス バソプレシンアゴニストとしてのチエエニルベンゾイルベンズアゼピン類
EP1149097A2 (en) 1999-02-04 2001-10-31 American Home Products Corporation Pyridobenzodiazepine and pyridobenzoxazepine carboxyamide vasopressin agonists
EP1149096B1 (en) 1999-02-04 2002-12-18 Wyeth Tricyclic pyridine n-oxides vasopressin agonists
GB0000079D0 (en) 2000-01-05 2000-02-23 Ferring Bv Novel antidiuretic agents
GB0015601D0 (en) * 2000-06-26 2000-08-16 Ferring Bv Novel antidiuretic agents

Also Published As

Publication number Publication date
HUE026442T2 (en) 2016-06-28
CN102918038A (zh) 2013-02-06
DK2552910T3 (en) 2015-04-07
SI2552910T1 (sl) 2015-06-30
SMT201500107B (it) 2015-07-09
JP2013523706A (ja) 2013-06-17
MX2012011382A (es) 2013-01-29
EP2552910A1 (en) 2013-02-06
JP5802737B2 (ja) 2015-11-04
HRP20150513T1 (hr) 2015-06-05
US9079881B2 (en) 2015-07-14
WO2011121308A1 (en) 2011-10-06
CA2795109A1 (en) 2011-10-06
RU2012146544A (ru) 2014-05-10
RU2559633C2 (ru) 2015-08-10
ES2538085T3 (es) 2015-06-17
KR20130023218A (ko) 2013-03-07
KR101792621B1 (ko) 2017-11-02
CA2795109C (en) 2018-04-17
US20140296213A1 (en) 2014-10-02
RS53956B1 (en) 2015-08-31
GB201005623D0 (en) 2010-05-19
PL2552910T3 (pl) 2015-07-31
CN102918038B (zh) 2015-09-09
EP2552910B1 (en) 2015-03-11
PT2552910E (pt) 2015-05-13

Similar Documents

Publication Publication Date Title
GB201020179D0 (en) New compounds
AP2012006641A0 (en) New compounds
GB201007286D0 (en) New compounds
IL223783A0 (en) Pro-neurogenic compounds
GB201015949D0 (en) Compounds
GB201008134D0 (en) Compounds
HK1187908A1 (zh) 咪唑並三嗪酮化合物
AP2012006640A0 (en) New aminopyrazoloquinazolines
EP2605658A4 (en) SPIROXAZOLIDINONVERBINDUNGEN
GB201007347D0 (en) Compounds
GB201112745D0 (en) New uses
EP2649050A4 (en) LINKS
GB201002563D0 (en) Compounds
ME02102B (me) Novi polimorf
GB201008209D0 (en) Compounds
GB201001688D0 (en) Compounds
GB201002216D0 (en) Compounds
GB201015537D0 (en) Compounds
GB201008210D0 (en) Compounds
GB201001796D0 (en) Compounds
GB201021494D0 (en) Compounds
GB201016221D0 (en) New compounds
GB201012899D0 (en) New compounds
GB201004307D0 (en) New compounds
GB201022042D0 (en) Compounds